Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Current Assets (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Current Assets for 9 consecutive years, with $162.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 10.18% year-over-year to $162.7 million, compared with a TTM value of $162.7 million through Dec 2025, up 10.18%, and an annual FY2025 reading of $162.7 million, up 10.18% over the prior year.
  • Current Assets was $162.7 million for Q4 2025 at Puma Biotechnology, up from $143.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $167.8 million in Q2 2021 and bottomed at $111.8 million in Q1 2023.
  • Average Current Assets over 5 years is $138.5 million, with a median of $137.3 million recorded in 2021.
  • The sharpest move saw Current Assets tumbled 31.88% in 2022, then rose 27.98% in 2024.
  • Year by year, Current Assets stood at $140.0 million in 2021, then decreased by 4.1% to $134.3 million in 2022, then increased by 16.31% to $156.2 million in 2023, then fell by 5.46% to $147.7 million in 2024, then increased by 10.18% to $162.7 million in 2025.
  • Business Quant data shows Current Assets for PBYI at $162.7 million in Q4 2025, $143.6 million in Q3 2025, and $136.6 million in Q2 2025.